Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer.
Inherited susceptibility to a wide variety of neoplasias (Li-Fraumeni syndrome), has been shown in studies of one cancer-prone family, to have an intriguing association with an aberrant c-raf-1 gene and inheritance of a radioresistant phenotype in their non-cancerous skin fibroblasts. This association together with observations that DNA topoisomerases, when defective, can introduce errors into DNA and that these enzymes are perturbed in vitro by serine/threonine kinases similar to raf encoded proteins, prompted investigation of DNA topoisomerase activity of the family's fibroblasts. Since radioresistance was transferred to murine cells (NIH-3T3) when the aberrant c-raf-1 gene from this family was transfected, we also examined transformants containing this and other oncogenes. V-raf/c-myc and EJ-ras transformants were examined, the former because the family's skin fibroblasts also have 3-8-fold elevated myc expression (not apparently relevant to radioresistance) and the latter because ras, like raf, conveys radioresistance. The family members' fibroblasts and the three transfected murine lines, showed a similar perturbation of a spermidine and ATP-dependent DNA catenation activity (typical of DNA topoisomerase II). There was a significant positive correlation (r = 0.93; P = 0.0026) between the degree of activation of topoisomerase II and one measure of radioresistance (the Dq value). Relaxation of DNA supercoiling (topoisomerase I activity and other DNA nicking enzymes) was not abnormal. Cytotoxicity assays and evaluation of the influence of topoisomerase II inhibitors on DNA/protein complex formation, corroborated the existence of a qualitative topoisomerase II defect in the family's cells and transfectants. Although the contention that the qualitative topoisomerase II abnormalities observed here may be associated with malfunction is highly speculative, these findings may be relevant to the mechanism of oncogenesis, not only in this family, but with raf and ras type oncogenes.
Cunningham
J M
JM
Molecular Cell Pathology Laboratory, Royal Free Hospital School of Medicine, London, UK.
Francis
G E
GE
Holland
M J
MJ
Pirollo
K F
KF
Chang
E H
EH
D000677:Amsacrine / Q000031:analogs & derivatives / Q000494:pharmacology; D001260:Ataxia Telangiectasia / Q000235:genetics; D002460:Cell Line / Q000502:physiology; D002467:Cell Nucleus / Q000201:enzymology; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D003561:Cytarabine / Q000494:pharmacology; D003593:Cytoplasm / Q000201:enzymology; D004260:DNA Repair; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism*; D004270:DNA, Circular / Q000378:metabolism; D004278:DNA, Superhelical / Q000378:metabolism; D005260:Female; D005347:Fibroblasts / Q000166:cytology / Q000201:enzymology / Q000648:ultrastructure; D015870:Gene Expression; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000201:enzymology / Q000235:genetics*; D009857:Oncogenes / Q000235:genetics; D011836:Radiation Tolerance / Q000235:genetics*; D013713:Teniposide / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors
D004270:DNA, Circular; D004278:DNA, Superhelical; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D003561:Cytarabine; C033073:4'-(9-acridinylamino)methanesulfon-o-anisidide; D013713:Teniposide; D004250:DNA Topoisomerases, Type II